Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

A recent study suggests that confounding may explain the increased risks of 

associated with prenatal prescribed opioid analgesic (POA) exposure.

Many obstetrician-gynecologists prescribe opioid analgesics to help manage their patients’ pregnancy pain. However, research has suggested a potential link between prenatal POA exposure and neurodevelopmental disorders.

It was not known if the association between prenatal POA exposure and neurodevelopmental disorders in children is causal or driven by confounding. In this retrospective study, investigators analyzed how the dose and duration of POA use during pregnancy were associated with autism and ADHD risk in children.

“We wanted to conduct this study to help provide more information for pregnant individuals and their physicians who are trying to make complex decisions about how to best manage pain during pregnancy,” said lead investigator Emma N. Clearly, BA, from Indiana University Bloomington, and colleagues, in a statement.

 “While this study is not able to rule out small increased risks with high amounts of exposure, the results suggest that there is not a causal effect of prescribed opioid analgesics on risk for two common neurodevelopmental disorders, providing more data to support decision-making.”

Using national register data from Sweden, this study examined a population-based cohort, with nearly half female (48.6%).

 The ASD cohort included 1,267,978 children born between July 1, 2007, and December 31, 2018, with a follow-up through 2021. Since ADHD is typically diagnosed later, investigators applied a shorter eligibility window, including 918,771 children born through December 31, 2015.

The team used test-mining algorithms to calculate cumulative dose and duration of POA exposure during pregnancy from filled prescriptions and to identify those prescribed on an “as needed” basis.

 Outcomes included inpatient or outpatient clinical diagnoses of ASD and ADHD or dispensed ADHD medications.

To address unmeasured confounding, the analysis incorporated several comparison groups: children whose birthing parent had a diagnosed painful condition but did not receive POAs, children whose birthing parent received POAs in the year prior to but not during pregnancy, and unexposed siblings.

Among the 1,267,978 children, 4.4% were exposed to POAs when in their mother’s womb. At 10 years old, the cumulative incidence of ASD was 3.6% and 2.9% among children exposed to high and low POA doses, respectively, compared with 2% among children unexposed to POAs.

Unadjusted models (hazard ratio [HR], 1.74;

1.63–1.87) and models adjusted for measured covariates (HR, 1.34

 95% CI, 1.24–1.44) showed that the cumulative maximum POA dose was associated with an increased risk of ASD. However, these associations were weak or nonexistent in alternative study designs, particularly when compared with children whose birthing parent had received POAs before, but not during, pregnancy (HR, 1.10; 95% CI, 1.00 – 1.21). The sibling comparison analysis showed no associations between ASD and POA exposure (HR, 0.99; 95% CI, 0.81 – 1.21).

Investigators noted that they did not assess the impact of extremely high doses and long durations of opioids due to limited data in the Swedish cohort.

“We are excited to share our findings because we believe that they have important clinical implications,” said investigator Ayesha C. Sujan, PhD, from Stanford University School of Medicine, in the statement.

 “Our findings suggest that the observed associations between prenatal exposure to opioid analgesics and two major neurodevelopmental disorders—autism and ADHD—are largely driven by factors leading up to opioid analgesic use rather than the opioid exposure itself. Our results, therefore, elucidate the critical need to provide pregnant individuals experiencing pain with psychosocial support and evidence-based pain management tools. These can include both pharmaceutical and non-pharmaceutical approaches.”

Cleary EN, Sujan AC, Rickert ME, et al. Prescribed opioid analgesic use in pregnancy and risk of neurodevelopmental disorders in children: A retrospective study in Sweden. 

. 2025;22(9):e1004721. Published 2025 Sep 16. doi:10.1371/journal.pmed.1004721

Prescribed opioid pain medications during pregnancy likely aren’t associated with increased risk of autism, ADHD. EurekAlert! Published September 16, 2025. Accessed September 17, 2025. https://www.eurekalert.org/news-releases/1097557

Articles

A recent study explored the potential link between prenatal prescribed opioid analgesic (POA) exposure and neurodevelopmental disorders such as autism spectrum disorder (ASD) and ADHD. The research, using Swedish national register data, analyzed the dose and duration of POA exposure during pregnancy. Findings suggest that the observed associations are likely due to confounding factors rather than a causal relationship. The study emphasizes the importance of providing pregnant individuals with psychosocial support and evidence-based pain management strategies, both pharmaceutical and non-pharmaceutical, to manage pregnancy-related pain effectively.

A study suggests associations between opioids during pregnancy and neurodevelopmental disorders are mainly due to confounding factors, not causal effects.


News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

ADHD

ADHD condition center page is a comprehensive resource for clinical news and insights on ADHD. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for ADHD.

Prenatal Opioid Pain Medications Likely Not Linked to Autism or ADHD Risk

Tim Smith joined the MJH Life Sciences team as an assistant editor for HCPLive in August 2022. He graduated from UC Berkeley with a degree in political science, working in multimedia journalism as a staff writer prior to joining MJH. In his spare time, he enjoys reading, watching TV, listening to podcasts, and rock climbing. You can contact him at 

 may be sustained or improved across disease measures through to Week 16, according to recent data.

These late-breaking findings were presented in a session at the 

European Academy of Dermatology and Venereology (EADV)

, with trial investigators including Kim A. Papp, MD, PhD, FRCPC, the founder and president of Probity Medical Research. Papp and colleagues had evaluated both the efficacy and the safety of izokibep, a novel interleukin (IL)-17A inhibitor, for patients living with moderate to severe HS.

The investigators highlighted HS as a chronic, systemic 

 marked by painful nodules, abscesses, and draining tunnels. Dysregulation of interleukin-17A (IL-17A) is said to be a key driver of the condition’s pathology. Izokibep, a novel molecule, has been engineered to selectively block IL-17A, given that it demonstrates exceptionally high binding affinity (Kd: 0.3 pM), has a small molecular size of 18.6 kDa—approximately 1-tenth that of a monoclonal antibody—and contains an albumin-binding domain designed to extend plasma half-life and potentially increase delivery to inflamed tissue.

The 16-week results from a randomized, double-blind, placebo-controlled, multicentre, phase 3 study were highlighted by Papp and coauthors in these late-breaking findings. The phase 2b/3 trial involved the recruitment of individuals living with moderate to severe HS who had a confirmed diagnosis for at least 6 months and lesions in 2 or more anatomical areas. These areas would include at least 1 Hurley stage II or III area.

Participants in Papp and colleagues' research were required to have a lack of a total abscess and inflammatory nodule (AN) count of 5 or greater. They would also have to report a history of intolerance, inadequate response, or contraindication to oral antibiotics. Previous treatment with IL-17 or IL-17 receptor inhibitors was also not permitted.

Eligible individuals involved as study subjects were randomized to 1 of the following cohorts of the analysis: izokibep 160 mg once weekly (QW), placebo QW with crossover to izokibep 160 mg QW, or izokibep 160 mg QW (continued treatment)
Key efficacy measures that the investigative team assessed at Week 16 and which were sustained through Week 76 included HiSCR50/75/90/100 (attainment of ≥50%, 75%, 90%, or 100% reduction in participants' AN count). Additionally, any shifts in the Dermatology Life Quality Index (DLQI), skin pain improvements of ≥3 points on the Numeric Rating Scale (NRS), reductions in AN count to ≤2, and flare frequency. Safety evaluations included treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), serious adverse events (SAEs), laboratory testing, and vital signs.

Izokibep was generally shown to be well tolerated, with Papp and colleagues concluded that no new safety concerns and no reported cases of candidiasis took place. Subjects being given izokibep experienced early and clinically meaningful improvements over placebo that were sustained through Week 16 and beyond.

More than one-third of treated subjects attained HiSCR75 at Week 16, and over 20% attained HiSCR100, suggesting complete clearance of AN lesions. Improvements were also observed in pain reduction, AN count, and quality of life scores, underscoring izokibep’s potential as a targeted therapy for moderate to severe HS.

Papp K, Bechara F, Kimball A, et al. Efficacy and safety of izokibep, a novel interleukin-17A inhibitor, in moderate to severe hidradenitis suppurativa: Week 16 results from a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. Presented at the 2025 European Academy of Dermatology and Venereology (EADV) Congress, Sept 17-20, 2025.

Izokibep, a novel IL-17A inhibitor, shows promise in treating moderate to severe hidradenitis suppurativa (HS), with sustained improvements in disease measures through Week 16. The phase 3 study demonstrated significant efficacy, with over one-third of participants achieving HiSCR75 and more than 20% achieving HiSCR100, indicating complete clearance of lesions. Izokibep was well tolerated, with no new safety concerns reported. The study highlights izokibep's potential as a targeted therapy for HS, offering improvements in pain, lesion count, and quality of life for patients.

This study highlights improvements with izokibep for HS, sustained or improved across disease measures through to Week 16.


Hidradenitis Suppurativa

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Izokibeb Effective in 16 Weeks Among Patients with Moderate to Severe Hidradenitis Suppurativa

Allysa Saggese, NP, is a nurse practitioner at Weill Cornell.

Collaboration and Innovation in MASH Management, With Allysa Saggese, NP

Metabolic dysfunction–associated steatohepatitis (MASH)

 remains a pressing concern in hepatology, presenting substantial risks of progression to advanced liver disease, cancer, and the need for transplantation.

Communicating this reality effectively to patients is a key step in care. Clear discussions about what fatty liver and fibrosis mean, and why they matter, help patients understand both the risks and the importance of early intervention, as explained by Allysa Saggese, NP, a nurse practitioner at Weill Cornell, at the 

2025 Gastroenterology & Hepatology Advanced Practice Providers (GHAPP) conference

Lifestyle measures continue to be the cornerstone of management, with diet, physical activity, and weight management forming the foundation of care even as pharmacologic options expand. Saggese emphasizes how framing these conversations in approachable ways, using terms like “activity” instead of “exercise” and emphasizing weight management rather than strict weight loss, can help make treatment goals more realistic and patient-centered.

“I talked a lot about the word choices I use and the way I describe the non-pharm bits to my patients, and making sure that's a collaborative relationship that I think comes from sitting down and just paying attention to what they're saying to you and trying to understand what you can do with what they've just told you,” Saggese explained.

On the pharmacologic front, the MASH treatment landscape is evolving, with 2 therapies now approved by the US Food and Drug Administration in the forms of resmetirom and semaglutide. With no strict sequencing guidelines, Saggese says clinicians and patients must work together to choose the therapy that best fits individual needs, preferences, and care plans.

“Some of the biggest gaps [we still see] in MASH care is identifying these patients. I think the base knowledge for other providers who aren't in the specialty can still be improved upon,” she said, explaining the importance of knowing things like how fibrosis can progress even when liver enzymes are normal.

While they may not have the nuanced expertise of hepatology specialists, Saggese says primary care providers can serve as a hub for identifying at-risk patients and directing them to advanced care. Better dissemination of guidelines around who to screen, when, and why could help bridge this gap.

Looking ahead, Saggese expresses excitement about having more therapies to offer patients in the future, explaining how this helps them feel like they have more control over outcomes, side effects, and treatment administration.

“I'm also excited for the better efficacy as we see things come out of trials and improve upon the last trial and improve upon the last drug, just getting better and better,” she said.

Brooks A. Resmetirom (Rezdiffra) Receives Historic FDA Approval for Noncirrhotic NASH. HCPLive. March 14, 2024. Accessed September 10, 2025. 

https://www.hcplive.com/view/resmetirom-rezdiffra-receives-historic-fda-approval-for-noncirrhotic-nash

Brooks A. FDA Approves Semaglutide (Wegovy) Injection 2.4 mg for Noncirrhotic MASH. HCPLive. August 15, 2025. Accessed September 10, 2025. 

https://www.hcplive.com/view/fda-approves-semaglutide-wegovy-injection-2-4-mg-for-noncirrhotic-mash

Videos

Saggese explains the importance of effective communication in MASH management and emphasizes the need for more therapies to offer patients.

Hepatology

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Ruth Masterson Creber, PhD | Image Credit: LinkedIn

Mobile integrated health (MIH) confers no additional benefit to either health status or 30-day readmissions for postacute patients with 

 compared to a transitions of care coordinator (TOCC), according to results from the Mighty-Heart trial.

HF is the leading cause of hospitalization among older adults in the US. It also has the highest 30-day all-cause readmission rates among Medicare beneficiaries. For those facing adverse social determinants of health, these readmissions can also create substantial financial and psychosocial burdens.

“Multiple interventions have been tested to improve care transitions and postdischarge outcomes for patients hospitalized for heart failure, yet few comparative effectiveness trials have evaluated alternative strategies,” Ruth Masterson Creber, PhD, Mary Crawford Professor of Nursing, Columbia University, and colleagues wrote. “Two possible interventions—mobile integrated health (MIH) and a transitions of care coordinator (TOCC)—have shown effectiveness in smaller trials or observational studies on postacute health care utilization and health status; however, they have not previously been directly compared in a randomized clinical trial.”

To this end, Creber and colleagues conducted the Mighty-Heart trial, a multicenter, pragmatic randomized clinical trial divided into 2 main cohorts. The MIH arm involved monitoring patients after hospital discharge and providing home-based interventions through community paramedics. This arm aimed to address symptom exacerbations and other unplanned readmission causes among patients with HF.

The TOCC arm instead consisted of a follow-up phone call from a nurse within 48-72 hours of discharge, during which time the nurse would assess the patient’s clinical status, identify unmet needs, and reinforce patient education. The nurse could also connect patients to care coordinators for non-emergent clinical and social needs.

The trial was conducted across 11 academic and community hospitals affiliated with New York Presbyterian and Mount Sinai Health. Patients were included if they were enrolled in Medicare or Medicaid, expected to be discharged home, and were ≥18 years old. Patients with a diagnosis of dementia or unstable psychiatric illness, as well as those with advanced HF, were excluded.

Patients were given a baseline survey aiming to capture self-reported sociodemographic information and baseline health status using the 23-item Kansas City Cardiomyopathy Questionnaire (KCCQ). After completion, patients were randomly assigned in a 1:1 ratio to either MIH or TOCC, stratified by health system.

The final analysis included 2003 of the 2012 patients randomized between 2021 and 2024 – 1005 were assigned to MIH and 998 to TOCC. Median age was 67 (19-98) years. A total of 1070 patients completed the KCCQ score; the observed mean (standard deviation [SD]) baseline KCCQ score was 46 (25) in the MIH group and 46 (26) in the TOCC group.

Investigators found no significant differences in 30-day KCCQ scores between the 2 groups (MIH, 9.82 vs TOCC, 7.99; adjusted mean difference: 1.83; 95% CI, -0.75 to 4.4; 

 = .16). Although age-specific subgroup analysis indicated MIH was associated with better health status among younger patients (ß = 4.4; 95% CI, 1.01 to 7.79), but not adults (ß = -1.87; 95% CI, -5.91 to 2.17). Age-by-treatment interaction was statistically significant (

A total of 408 participants (204 with MIH and 204 with TOCC) were readmitted within 30 days of discharge. The team found no significant main treatment effects on 30-day all-cause readmissions in unadjusted (odds ratio [OR], 0.99; 95% CI, 0.83 to 1.19; 

 = .95) or adjusted analyses (OR, 0.97; 95% CI, 0.8 to 1.16; 

 = .72). A total of 259 experienced an HF specific readmission within 30 days, without significant main treatment effects on 30-day HF specific readmissions in unadjusted (OR, 0.9; 95% CI, 0.74 to 1.09; 

 = .27) or adjusted (OR, 0.9; 95% CI, 0.74 to 1.1; 

Ultimately, investigators found no significant differences between MIH and TOCC – however, the finding of significantly worse health status outcomes with TOCC among younger participants is consistent with prior studies.

“However, the exploratory findings that MIH may have supported better health status in younger patients underscores the importance of further research to better define optimal transition of care strategies for patients hospitalized with heart failure,” Creber and colleagues wrote.

Masterson Creber R, Daniels B, Reading Turchioe M, et al. Mobile Integrated Health vs a Transitions of Care Coordinator for Patients Discharged After Heart Failure: The Mighty-Heart Randomized Clinical Trial. JAMA Intern Med. Published online September 15, 2025. 

Masterson Creber RM, Daniels B, Munjal K, et al. Using Mobile Integrated Health and telehealth to support transitions of care among patients with heart failure (MIGHTy-Heart): protocol for a pragmatic randomised controlled trial. BMJ Open. 2022;12(3):e054956. Published 2022 Mar 10. 

The Mighty-Heart trial compared mobile integrated health (MIH) and transitions of care coordinator (TOCC) interventions for postacute heart failure patients. Conducted across 11 hospitals, the trial found no significant differences in 30-day readmissions or health status between the two groups. However, MIH showed better health outcomes in younger patients, suggesting potential age-specific benefits. Both interventions were tested for their effectiveness in improving care transitions and postdischarge outcomes, but neither demonstrated superiority in reducing readmissions or enhancing overall health status in the general patient population.

When compared to transitions of care coordinators, MIH saw no additional benefit to either health status or 30-day hospital readmissions for postacute patients with HF.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Mighty-Heart: Mobile Integrated Health Offers No Benefit in Heart Failure Readmissions

European Association of Dermatology and Venereology (EADV) 2025 Congress

 is shedding light on real-world use of abrocitinib (Cinbiqo) in patients with 

“One of the things that's lacking, often for our medications, beyond clinical trial data, is real-world data, and specifically real-world data that is heterogeneous, meaning that it's gathered across a large population, rather than a single center or a single practice or a single person,” explained study investigator Raj Chovatiya, MD, PhD, dermatologist and clinical associate professor at Rosalind Franklin University Chicago Medical School, founder and director of the Center for Medical Dermatology and Immunology Research in Chicago, in an interview with HCPLive. “And this particular analysis with abrocitinib is one of the bigger, newer analyses that we have.”

An oral JAK1 inhibitor, abrocitinib received approval for moderate-to-severe atopic dermatitis from the US Food and Drug Administration for adults in 2022 and adolescents in 2023, but real-world evidence on its use remains limited.

At EADV 2025 Congress, a recent retrospective observational study leveraged the OMNY Health Database to understand the characteristics of patients initiating abrocitinib in outpatient dermatology practices nationwide. The analysis included adolescents and adults with moderate-to-severe atopic dermatitis who received abrocitinib between January 2022 and February 2025.

Data were drawn from general and dermatology electronic health records (EHRs) linked to open claims. Patients were required to have a confirmed AD diagnosis, with exclusions consistent with product labeling.

A total of 315 patients were identified, of whom 8.3% were adolescents and 91.7% were adults. Of these patients, 35% had prior biologic exposure, with dupilumab representing the most common biologic therapy (34.6%). Investigators noted oral prednisone use was also frequent (49.2%).

Assessment of comorbidities revealed overweight or obesity (43.5%), anxiety (41.3%), allergic rhinitis (38.7%), contact dermatitis (37.8%), and depression (34.3%) were the most common comorbidities.

Investigators found a greater proportion of adolescents initiated therapy at the 200-mg dose compared with adults (23.1% vs 13.8%).

Only 13.3% of patients had documented clinician- or patient-reported severity measures at baseline or within 42 days prior to starting abrocitinib. Among this group, 95.2% reported involvement of the upper extremities and 52.8% reported severe itch scores on the Itch Numeric Rating Scale, while clinician-reported disease severity by Investigator’s Global Assessment was most commonly rated as moderate (40.5%).

Real-World Data Shed Light on Abrocitinib Use for Atopic Dermatitis, With Raj Chovatiya, MD, PhD

Relevant disclosures for Chovatiya include AbbVie, Amgen, AnaptysBio, Apogee Therapeutics, Arcutis, Argenx, ASLAN Pharmaceuticals, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, CLn Skin Care, Dermavant, Eli Lilly, EMD Serono, FIDE, Formation Bio, Galderma, Genentech, GSK, Incyte, LEO Pharma, L'Oréal, Nektar Therapeutics, Novartis, Opsidio, Pfizer, RAPT, Regeneron, Sanofi, Sitryx, Takeda, TRex Bio, and UCB.

 Abrocitinib Treatment for Moderate-to-Severe Atopic Dermatitis Observed in Electronic Health Records and Administrative Claims in a US-Based Real-World Dermatology Setting: Patient Characteristics and Baseline Disease Severity

. Presented at the European Association of Dermatology and Venereology (EADV) 2025 Congress. Paris, France. September 17-21, 2025.

Pfizer Inc. U.S. FDA Approves Pfizer’s CIBINQO® (abrocitinib) for Adults with Moderate-to-Severe Atopic Dermatitis | Pfizer. Pfizer.com. Published January 14, 2022. Accessed September 17, 2025. 

https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-pfizers-cibinqor-abrocitinib-adults

Pfizer Inc. FDA Approves Pfizer’s Supplemental New Drug Application for CIBINQO® (abrocitinib) | Pfizer. www.pfizer.com. Published February 10, 2023. Accessed September 17, 2025. 

https://www.pfizer.com/news/press-release/press-release-detail/fda-approves-pfizers-supplemental-new-drug-application

A recent study reveals diverse real-world data on abrocitinib use for atopic dermatitis.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

New data reveals bimekizumab offers sustained disease control for hidradenitis suppurativa, improving patient quality of life for 3 years.

BE HEARD: Bimekizumab Benefit in Hidradenitis Suppurativa Persists for 3 Years

Icotrokinra outperforms deucravacitinib in achieving skin clearance for plaque psoriasis, offering a promising new oral treatment option.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

ICONIC-ADVANCE: Icotrokinra Beats Deucravacitinib for Plaque Psoriasis

These 24-week, interim data from the phase STOP-HS study highlight the impacts of povorcitinib on patients with hidradenitis suppurativa (HS).

Povorcitinib Improves Moderate to Severe Hidradenitis Suppurativa at Week 24

Eingun James Song, MD, highlights recent phase 4 data on risankizumab for patients with moderate to severe scalp and genital psoriasis.

Spotlighting New Data on Risankizumab for Scalp and Genital Psoriasis, With Eingun James Song, MD

Shawn Kwatra, MD, highlights his team’s findings presented at EADV on the efficacy of dupilumab in treating prurigo nodularis.

Discussing New Phase 3 Results on Dupilumab for Prurigo Nodularis, With Shawn Kwatra, MD

A new meta-analysis has contrasted the association between the 2 conditions against the general population, psoriasis, rheumatoid arthritis, and ankylosing spondylitis.

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

Psoriatic Arthritis

On the HCPLive psoriatic arthritis page, resources on the topics of medical news and expert insight into PsA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on arthritis, and more.

Psoriatic Arthritis Strongly Associated with Metabolic Syndrome and Components

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

The EXHALE-4 study evaluating the oral small molecule has met its primary endpoint of improving pre-BD FEV1.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Dexpramipexole Oral Add-On for Asthma Significantly Improves Lung Function Over Placebo

Nearly a third of patients with lupus in APPEAL reported falls, with disease activity, depressive symptoms, and medication use among key risk factors.

Falls Common in Systemic Lupus Erythematosus Regardless of Age

Abigail Brooks is an assistant editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

Compared with non-use, taking semaglutide or tirzepatide was associated with improved rheumatoid arthritis disease activity and cardiovascular risk.

Rheumatoid Arthritis

The HCPLive rheumatoid arthritis page is a comprehensive resource for clinical news and insights on arthritis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for RA, and more.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

GLP-1 RA Use Improves Disease Activity, Cardiovascular Risk in Rheumatoid Arthritis

Avapritinib shows significant long-term benefits for indolent systemic mastocytosis while maintaining a favorable safety profile.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Latest News

Prenatal Opioid Pain Medications Likely Not Linked to Autism or ADHD Risk

Izokibeb Effective in 16 Weeks Among Patients with Moderate to Severe Hidradenitis Suppurativa

Collaboration and Innovation in MASH Management, With Allysa Saggese, NP

Mighty-Heart: Mobile Integrated Health Offers No Benefit in Heart Failure Readmissions

Real-World Data Shed Light on Abrocitinib Use for Atopic Dermatitis, With Raj Chovatiya, MD, PhD